Zymeworks (ZYME) Earnings Date & Reports

Key Takeaways

• Zymeworks Inc. is scheduled to report its third quarter 2026 financial results after the market close on November 9, 2026.
• Consensus estimates point to a dramatic swing to profitability, with analysts projecting earnings per share (EPS) of roughly $2.41 and revenue near $227 million, driven largely by anticipated milestone payments.
• In its prior quarter, the company posted a wider-than-expected loss, with EPS of -$0.62 and revenue of $3.23 million, reflecting the roll-off of prior-year milestones.
• Investors are closely watching the recognition of a potential $250 million milestone from Jazz Pharmaceuticals tied to U.S. approval of zanidatamab in first-line gastroesophageal adenocarcinoma (GEA).
• Management has guided to full-year 2026 revenue of $278 million to $292 million, below the consensus revenue estimate of about $308 million at the time it was issued.

Earnings Context and Why It Matters

Zymeworks is a clinical-stage biotechnology company managing a portfolio of licensed healthcare assets while advancing its own pipeline of multifunctional biotherapeutics. Because its near-term revenue depends heavily on collaboration and milestone payments rather than recurring product sales, quarterly results can swing sharply from period to period. The upcoming report carries unusual weight because it may capture the recognition of a substantial milestone tied to zanidatamab, its most advanced partnered program. For investors, the print will clarify both the trajectory of near-term revenue and the durability of the company's cash position, which management says could fund operations beyond 2028 when combined with anticipated regulatory milestone payments.

Earnings Expectations

Wall Street's outlook for the third quarter marks a striking departure from Zymeworks' recent results. According to consensus data compiled by MarketBeat, analysts expect EPS of approximately $2.41, within a wide range of $2.14 to $2.68, alongside revenue near $227 million. That compares with a net loss and just $3.23 million in revenue in the second quarter of 2026, when results fell short of the -$0.56 consensus EPS estimate and the $4.54 million revenue estimate.

The unusually wide dispersion in estimates reflects uncertainty around the timing of milestone recognition. Management previously indicated that potential approvals could trigger near-term milestone payments of $250 million from Jazz Pharmaceuticals upon U.S. approval of zanidatamab in first-line HER2-positive (a protein that promotes aggressive cancer growth) gastroesophageal adenocarcinoma (GEA), and $50 million from BeOne upon approval in China. The U.S. Food and Drug Administration's target decision date, known as a PDUFA (Prescription Drug User Fee Act) date, was set for August 25, 2026.

On the guidance front, Zymeworks issued full-year 2026 revenue guidance of $278 million to $292 million in late September, which came in below the consensus estimate of roughly $308 million at the time. Beyond the headline figures, investors will monitor operating expense trends, the company's $403.8 million cash position, and progress on its $125 million share repurchase program.

AI Screener

For investors tracking earnings events like Zymeworks' third-quarter report, Tickeron's AI Screener offers a streamlined way to filter the market. The AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors sort thousands of securities based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can apply customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics to surface trade ideas, breakout candidates, and trending stocks more efficiently than manual screening. Explore the AI Screener to support your own research process.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is shaped by a tension between near-term financial disappointment and a potentially transformative catalyst. The company's recent quarters have been marked by shrinking revenue as prior-year milestones rolled off, and the stock has shown limited post-earnings drift following its last release. At the same time, the prospect of a nine-figure milestone tied to zanidatamab's U.S. approval in first-line GEA has refocused attention on the company's ability to convert regulatory progress into cash. Key risk factors include the precise timing of milestone recognition, whether royalty and collaboration revenue is building as expected, and any updates to expense or cash-runway guidance that could temper the positive headline numbers.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors should watch several forward-looking signals. The first is guidance: whether management reaffirms or adjusts its full-year revenue outlook and how the company frames the timing of remaining milestone payments tied to zanidatamab approvals in the U.S., Europe, Japan, and China.

The second area is the commercial trajectory of zanidatamab. As royalty revenue begins to build from product sales, investors will look for evidence that recurring income is starting to offset the lumpiness of milestone-driven revenue. Management has said it expects royalties to grow over time as commercial sales of zanidatamab increase.

Finally, the clinical pipeline deserves attention. Zymeworks continues to advance early-stage antibody-drug conjugate (ADC) programs and has adjusted timelines for some candidates, including moving an investigational new drug (IND) filing for ZW1528 into 2027. Updates on enrollment progress, data-readout timing, and any new partnership activity will be important signals about the company's ability to sustain long-term value creation beyond its current milestone catalysts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations